Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay
Authors:
- Jolanta M. Siller-MatulaJSJolanta M. Siller-Matula
- Simon PanzerSPSimon Panzer
- Bernd JilmaBJBernd Jilma
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Platelets
- Vol. 19 (7) , 551-554
Abstract
The platelet vasodilator-stimulated phosphoprotein (VASP) phosphorylation test is a new platelet function assay used to determine responsiveness to clopidogrel. We investigated if a commercially available VASP assay has a good reproducibility when conducted with half or quarter of the recommended volume of reagents. Secondly, we hypothesized that the platelet reactivity indexes (PRI) in the VASP assay, calculated with three possible measurements of fluorescence intensities (FI): mean, geometric mean or median, are not equal. The VASP assay was performed in 280 patients on clopidogrel therapy and 35 volunteers without clopidogrel therapy. The VASP assay had an excellent reproducibility even if half or quarter of the volume of reagents recommended by the manufacturer were used: there was a high correlation between analyses with full vs. half and full vs. quarter volumes of reagents (r = 0.94; r = 0.93; p < 0.001, respectively). The PRI index was 4% higher when calculated with the geometric mean FI or the median FI (83%) as compared to the mean FI (80%; p < 0.001) in healthy volunteers without clopidogrel therapy. The PRI was 6% higher when calculated with the geometric mean FI or the median FI (52%) as compared to the mean FI (49%; p < 0.01) in patients on clopidogrel therapy. In conclusion, using half of the volume of reagents may constitute a cost-saving strategy for any laboratory performing the assay. Secondly, differences in calculation of PRI (mean, geometric mean or median fluorescence intensities) significantly contribute to the variability of results and reported cut-off values of the PRI. This variability can be easily avoided to facilitate comparison of data between different laboratories.Keywords
This publication has 21 references indexed in Scilit:
- Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel ResistanceJACC, 2008
- Will Measuring Vasodilator-Stimulated Phosphoprotein Phosphorylation Help Us Optimize the Loading Dose of Clopidogrel?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.JACC, 2008
- The active metabolite of prasugrel effectively blocks the platelet P2Y12receptor and inhibits procoagulant and pro-inflammatory platelet responsesPlatelets, 2008
- Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1and P2Y12receptors: A new finding that may influence the design of anti-thrombotic agentsPlatelets, 2008
- A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometryThrombosis and Haemostasis, 2008
- Clopidogrel resistance — The cardiologist's perspectivePlatelets, 2007
- ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndromeThrombosis and Haemostasis, 2007
- The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosisThrombosis and Haemostasis, 2007
- Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in plateletsPlatelets, 2003
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986